Idiopathic Multicentric Castleman Disease in Children: A Single-Center Retrospective Analysis

JunYe Du,Jiafeng Yao,Honghao Ma,Li Li,Ang Wei,Liping Zhang,Dong Wang,Zhi Gang Li,Rui Zhang,Tianyou Wang
DOI: https://doi.org/10.21203/rs.3.rs-4323200/v1
2024-01-01
Abstract:Abstract Objective: To investigate the clinical features, pathological phenotype, treatment and prognosis of idiopathic multicenter Castleman disease (iMCD)in children. Methods:From January 2017 to September 2023, basic information, laboratory tests, treatment and prognosis of children diagnosed with iMCD who attended Beijing Children's Hospital of Capital Medical University were collected. Results: A total of 9 children were enrolled, with a median age of onset of median 11 (2-15) years, 6 males and 3 female. 3 cases were pathologically typed as plasma cell type, 1 case was mixed type, and the remaining 5 cases were hyaline vascular type. 9 children received different regimens of chemotherapy. The median follow-up time was 26 (13, 58) months, with no deaths, 7/9 cases showing improvement, 1/9 cases showing stable condition, and 1/9 cases showing active condition. Conclusion: Children with multicentric CD often have systemic symptoms, lymph node enlargement and related compression symptoms are the most common manifestations, followed by fever, malaise and other systemic symptoms. Anti-IL-6-based therapy combined with hormones lenalidomide and other medications have a specific therapeutic effect on multicentric CD.
What problem does this paper attempt to address?